About this trial
Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.
Eligibility criteria
Qualifiers
Age >= 13 years.
Histopathologically confirmed differentiated or poorly differentiated thyroid cancer.
American Thyroid Association (ATA) intermediate or high-risk thyroid cancer and planning on treatment using I-131.
Metastatic disease on imaging (CT, MRI, ultrasound or FDG PET), and considering localized therapy such as surgery and radiation therapy.
Disqualifiers
Unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
Known pregnancy.
Trial design
Treatments tested in this trial
- Iodine-124
- Positron Emission Tomography (PET)/Computerized tomography (CT)
Treatment groups
Sponsors and collaborators
Thomas Hope
Lead sponsor
University of California, San Francisco
Sponsor institution
United States Department of Defense
Collaborator